BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11023518)

  • 21. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S; Haimovich J; Hollander N
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH; Bailey-Wood R
    Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma.
    Garderet L; Mazurier C; Pellat-Deceunynck C; Karim A; Baudin B; Funck-Brentano C; Bouchet S; Geffroy A; Bataille R; Gorin NC; Lopez M
    Leuk Lymphoma; 2006 Jul; 47(7):1340-7. PubMed ID: 16923566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses.
    Muraro S; Bondanza A; Bellone M; Greenberg PD; Bonini C
    Blood; 2005 May; 105(9):3596-604. PubMed ID: 15650058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
    Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
    Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
    Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
    Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
    Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
    Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
    Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
    Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
    Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
    Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
    Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
    Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
    Hong S; Qian J; Yang J; Li H; Kwak LW; Yi Q
    Cancer Res; 2008 Oct; 68(20):8456-64. PubMed ID: 18922919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
    Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
    Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.